Scholarlink

<p>This paper proposes a conceptual ethical framework to guide decision-making around blood-based biomarker (BBM) testing for Alzheimer’s disease in primary care, where patients often present with cognitive impairment and multiple chronic conditions. Grounded in current evidence and ethical principles, it addresses clinical benefit, patient values, risk, and justice. Developed by a multidisciplinary team, the framework is illustrated through real-world case scenarios and highlights future research needs to support ethical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An ethical framework for the clinical use of Alzheimer’s disease biomarker testing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月19日

查看全文
  • Catherine E. A. Scipion,
  • Michelle M. Mielke,
  • Allyson C. Rosen,
  • Suzanne E. Schindler,
  • Jalayne J. Arias

摘要

This paper proposes a conceptual ethical framework to guide decision-making around blood-based biomarker (BBM) testing for Alzheimer’s disease in primary care, where patients often present with cognitive impairment and multiple chronic conditions. Grounded in current evidence and ethical principles, it addresses clinical benefit, patient values, risk, and justice. Developed by a multidisciplinary team, the framework is illustrated through real-world case scenarios and highlights future research needs to support ethical implementation.